The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Palvella Therapeutics is set to expand Phase III SELVA trial to include subjects aged three to five years old.

The mechanistic (or mammalian) target of rapamycin (mTOR) signaling pathway, implicated in rapid antidepressant effects, was investigated for its role in KNT-127's action. The researchers injected ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...

Am J Health Syst Pharm. 2010;67(24):2095-2106. Temsirolimus is primarily metabolized by the cytochrome P-450 (CYP) 3A4 isoenzyme to five major metabolites, with sirolimus being the principal ...

tells India Today that Rapamycin, also known as sirolimus, was initially discovered by a bacterium on Easter Island (Rapa Nui ...

Some scientists say that rapamycin can reduce inflammation "by inhibiting a signaling pathway in the body called mTOR — which ...